Truist Securities Reiterates Buy on Bristol-Myers Squibb, Maintains $84 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Bristol-Myers Squibb (NYSE:BMY) and maintained an $84 price target.
October 06, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on Bristol-Myers Squibb and maintained an $84 price target.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Bristol-Myers Squibb. The maintained price target of $84 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100